Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 4

Completed

Brief Summary: This clinical study will evaluate the safety and tolerability of combination treatment of nintedanib and pirfenidone in participants with IPF. Eligible participants must have received pirfenidone for at least 16 weeks on a stable dose. Nintedanib will be added on Day 1 of the study as a combination treatment for IPF for 24 weeks.

Recruitment & Eligibility

Inclusion Criteria

Participants who are on pirfenidone for at least 16 weeks and on a stable dose (defined as 1602-2403 mg/day) for at least 28 days at the start of Screening; the dose must be expected to remain in that range throughout the study
Documented diagnosis of IPF, per the Investigator per using the criteria of the 2011 American Thoracic Society / European Respiratory Society / Japanese Respiratory Society / Latin American Thoracic Association guidelines
Participants with percent predicted forced vital capacity (FVC) more than or equal to (>=) 50 percent (%) and percent predicted carbon monoxide diffusing capacity (DLco) >=30% at Screening
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of less than (<) 1% per year, during the treatment period and for at least 3 months after the final Follow-up Visit
For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm during the treatment period and for at least 4 months after the final Follow-up Visit

Exclusion Criteria

Participants with clinical evidence of active infection
Participant with any new or ongoing moderate or severe adverse reaction considered by the Investigator to be related to pirfenidone, or an pirfenidone treatment interruption in the 28 days before the start of Screening
Any condition that is likely to result in death in the 12 months after the start of Screening
Lung transplantation anticipated or any planned significant surgical intervention
Known hypersensitivity to the active substance or any excipient of either pirfenidone or nintedanib
Mild (Child Pugh A), moderate (Child Pugh B), or severe (Child Pugh C) hepatic and/or severe renal impairment
History of gastrointestinal (GI) tract perforation, unstable or deteriorating cardiac or pulmonary disease (other than IPF), long QT syndrome, alcohol or substance abuse in the 2 years before the start of screening, use of any tobacco product in the 12 weeks before the start of screening
Bleeding risk
Use of Cytochrome P450 (CYP) 1A2 (CYP1A2) inhibitors (for example, fluvoxamine, enoxacin) and/or use of inhibitors of P-glycoprotein (for example, ketoconazole, erythromycin) or CYP3A4 (for example, ketoconazole, erythromycin) or their inducers (for example, rifampicin, carbamazepine, phenytoin, St John's wort) in the 28 days before the start of Screening
Pregnancy or lactation
Hypersensitivity to peanuts and/or soy
Use of pirfenidone and/or nintedanib in a clinical study protocol in the 28 days before the start of screening

Arm && Interventions

Group	Intervention	Description
Pirfenidone+Nintedanib	Nintedanib	Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.
Pirfenidone+Nintedanib	Pirfenidone	Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day	Week 24

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Adverse Events and Serious Adverse Events	Baseline up to Week 28	An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Total Number of Participant Days of Combination Treatment With Pirfenidone and Nintedanib	Baseline up to Week 24
Percentage of Participants Who Discontinue Pirfenidone, Nintedanib, or Both Study Treatments Because of Adverse Events Before the Week 24 Visit	Baseline up to Week 24
Total Number of Days From the Initiation of Combination Treatment to Discontinuation of Pirfenidone, Nintedanib, or Both Study Treatments	Baseline up to Week 24

Locations (38): David Geffen School of Medicine at UCLA;Division of Pulmonary & Critical Care/ Department of Medic
🇺🇸
Los Angeles, California, United States
Stanford University School of Medicine ; Pulmonary/Critical Care Medicine
🇺🇸
Stanford, California, United States
Sarasota Memorial Hospital
🇺🇸
Sarasota, Florida, United States
Beth Israel Deaconess Medical Center
🇺🇸
Boston, Massachusetts, United States
University of Michigan Health System
🇺🇸
Ann Arbor, Michigan, United States
Cardio-Pulmonary Associates of St. Luke's Hospital
🇺🇸
Chesterfield, Missouri, United States
Creighton University
🇺🇸
Omaha, Nebraska, United States
Atlantic Respiratory Institute
🇺🇸
Summit, New Jersey, United States
Mount Sinai School of Medicine
🇺🇸
New York, New York, United States
Columbia University Medical Center
🇺🇸
New York, New York, United States
Scroll for more (28 remaining)
David Geffen School of Medicine at UCLA;Division of Pulmonary & Critical Care/ Department of Medic
🇺🇸Los Angeles, California, United States